Little Is Known About MSA. We Want to Change That.
There is no cure for MSA, and there are currently no treatments available to delay the progress of the neurodegeneration it causes in the brain. There are no known genetic risk factors or early biological markers of the disease, and the typical timeframe from diagnosis to death is less than 10 years.
Research is critical for this rare and devastating disorder to offer hope to MSA patients and their families. We believe that the research we fund will help not only MSA patients, but patients with other neurological disorders such as Parkinson’s, Alzheimer’s and Dementia as well.
Cutting Edge Research
The Translational Genomics Research Institute (TGen) is a leader in the field of genomics – the study of a complete set of DNA.
They have demonstrated success with whole genome sequencing on patients and families with rare disorders. TGen focuses on helping patients through cutting edge translational research.
While MSA remains largely a mystery, there is a global effort already underway to try and understand this terrible disease.
The goal is to identify genes associated with the disease by studying MSA at the DNA-level.
TGen’s international registry allows for whole genome sequencing on those suffering from MSA as well as their families. We hope this study helps isolate genetic changes that may be causing or associated with MSA.
A “Global MSA Taskforce” has been assembled to connect scientists from around the world. They will share resources and techniques for research and new therapy development.
Through this research, groundbreaking tactics to combat MSA could be developed, such as:
- New ways to diagnose early-stage MSA
- Individualized treatments that could immediately benefit MSA patients
- Methods to calculate one’s risk of MSA before the onset of symptoms
- New prevention approaches and techniques
Recently, researchers from 12 countries and 30 academic institutions gathered to develop a “Research Roadmap” to help guide research and treatment advancement in MSA.